Neuromuscular   

If using rituximab, how often are you treating the patient? E.g., every 6 months or alternatively, do you use a serological test like B cell number, M...

Can you elaborate on reasons for a non-quantifiable SPEP and how does one follow the paraprotein?

E.g., a patient with newly diagnosed CIDP who is wheelchair-bound.

When it seems fairly certain that this is a drug effect is it something that can just be monitored or requires a change in approach?